UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2020

 

LIQUIDIA TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-38601 20-1926605
(State or other jurisdiction
of incorporation) 		(Commission
File Number) 		(IRS Employer
Identification No.)

 

419 Davis Drive, Suite 100, Morrisville, North Carolina   27560
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (919) 328-4400

 

 
(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 8.01 Other Events.

 

On July 24, 2020, Liquidia Technologies, Inc., a Delaware corporation (the “Company”), responded to the announcement that United Therapeutics Corporation, a Delaware corporation (“UTC”), filed an amended complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware. The amended complaint asserts infringement by the Company of an additional recently issued U.S. Patent No. 10,716,793 relating to UTC’s Tyvaso®, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH). The initial complaint, filed in June 2020 by UTC claiming infringement by the Company of U.S. Patent Nos. 9,604,901 and 9,593,066, was in response to the New Drug Application the Company filed with the U.S. Food and Drug Administration requesting approval to market LIQ861, a dry powder inhalation of treprostinil for the treatment of PAH.

 

A copy of the press release announcing the filing of UTC’s amended complaint against the Company is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No. 		  Exhibit
99.1   Press Release of Liquidia Technologies, Inc., dated July 24, 2020.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

July 24, 2020 Liquidia Technologies, Inc.
   
   
  By: /s/ Richard D. Katz, M.D.
    Name: Richard D. Katz, M.D.
    Title: Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

 

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent

 

RESEARCH TRIANGLE PARK, N.C., July 24, 2020 - Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics Corporation (UTC) filed an amended complaint in its patent infringement action under the Hatch-Waxman Act against the Company in the U.S. District Court for the District of Delaware. The amended complaint asserts infringement of an additional recently issued U.S. Patent No. 10,716,793 (‘793) allegedly relating to UTC’s Tyvaso®, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH).

 

The lawsuit was originally filed in June 2020 in response to Liquidia’s filing of a New Drug Application (NDA) for LIQ861 with the U.S. Food and Drug Administration (FDA). The original complaint asserted infringement of U.S. Patent Nos. 9,604,901 (’901) and 9,593,066 (’066) and triggered the statutory 30-month regulatory stay on the FDA approval of LIQ861. On July 16, 2020, Liquidia filed its Answer to UTC’s original Complaint including Counterclaims of invalidity, non-infringement, and Orange Book de-listing of the ’901 and ’066 patents.

 

Although UTC’s amended complaint brings the ‘793 patent into the pending lawsuit, the statutory 30-month stay on regulatory approval is not associated with the allegations of infringement of the ‘793 patent and the allegations of infringement of this patent should have no effect on the FDA’s review of the LIQ861 NDA.

 

“We firmly believe that, if approved, LIQ861 will benefit PAH patients and the physicians who treat them by providing an alternative treatment option that delivers higher, tolerable doses through a convenient, inhaled route of administration,” said Neal Fowler, Chief Executive Officer of Liquidia. “We stand firm in our commitment to PAH patients and will vigorously defend against any attempt to hinder our ability to bring LIQ861 forward.”

 

About Liquidia

 

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

 

 

 

 

 

Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for LIQ861, the timeline related to our two petitions for inter partes review with the Patent Trial and Appeal Board, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, including the risk that our proposed acquisition of RareGen, LLC is not consummated, the impact of the coronavirus (COVID-19) outbreak on our company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information

 

Media:

Michael Parks

Corporate Communications

484.356.7105

michael.parks@liquidia.com

 

 

 

 

 

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com